Penn Medicine, University of Pennsylvania Health System, shared on LinkedIn:
“A novel personalized mRNA vaccine, tested at Penn Medicine under lead investigator Dr. Ravi Amaravadi, has become the first of its kind to show positive results in a late stage clinical trial for melanoma. By analyzing unique genetic mutations in a patient’s tumor, this therapy trains the immune system to recognize, target, and destroy remaining cancer cells to prevent recurrence.
For trial participants like Denise Fitzsimmons, a grandmother from Birdsboro, Pennsylvania who has remained cancer free for two years, the study offers real hope for enduring remission.
Built on the groundbreaking mRNA platform pioneered by Penn’s own Nobel laureates Dr. Drew Weissman and Dr. Katalin Karikó, this advancement signals a promising future for personalized oncology.
Read the full story from The Philadelphia Inquirer.”
You may also be interested in: Pfizer to Present 45 Abstracts at ESMO 2026, With Data in Breast, Genitourinary, Lung Cancers and Melanoma
